Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-11 00:00:00 ET · period of report 2022-04-08 · accession 0001708138-22-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-11 | 2022-04-08 | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $736.21 | -5,606 | 25.1K | -18% | -$4.13M |
| DM | 2022-04-11 | 2022-04-08 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $364.23 | +7,450 | 27.2K | +38% | +$2.71M |
| DM | 2022-04-11 | 2022-04-08 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -7,450 | 5,000 | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-08 | F | D | 3,451 | $736.21 | 26,615 | D | — | — | |
| 2 | Common | Common Stock | 2022-04-08 | M | A | 5,000 | $270.43 | 30,066 | D | — | — | |
| 3 | Common | Common Stock | 2022-04-08 | F | D | 2,155 | $736.21 | 25,066 | D | — | — | |
| 4 | Common | Common Stock | 2022-04-08 | M | A | 2,450 | $555.67 | 27,221 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-04-08 | M | D | 2,450 | $0.00 | 10,000 | D | $555.67 · — to 2025-12-16 | 2,450 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-04-08 | M | D | 5,000 | $0.00 | 5,000 | D | $270.43 · — to 2023-12-13 | 5,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |